BridgeBio Pharma美股招股说明书(2026-08-14版)

BridgeBio Pharma, Inc. Common Stock The selling stockholder identified in this prospectus supplement is offering 5,000,000 shares of our commonstock, par value $0.001 per share (the “common stock”). We are not selling any shares of common stock underthis prospectus supplement and will not receive any of the proceeds from the sale of the shares of common stocksold by the selling stockholder. Our common stock is listed on The Nasdaq Global Select Market under the symbol “BBIO.” On August13, 2026,the last reported sale price of shares of our common stock on The Nasdaq Global Select Market was $81.21 pershare. Investing in our securities involves a high degree of risk. See the section entitled “Risk Factors” beginning onpage S-5of this prospectus supplement and elsewhere in this prospectus supplement and the accompanying baseprospectus for a discussion of information that should be considered in connection with an investment in oursecurities. (1)The selling stockholder will pay all brokerage expenses, fees, and discounts, if any, in connection with the sale of the shares of theselling stockholder’s common stock. See “Underwriting (Conflicts of Interest)” beginning on page S-15of this prospectus supplementfor additional information. Neither the Securities and Exchange Commission nor any state securities commission has approved ordisapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement.Any representation to the contrary is a criminal offense. The underwriters expect to deliver the shares to purchasers on or about August 17, 2026. TABLE OF CONTENTS Prospectus Supplement ABOUT THIS PROSPECTUS SUPPLEMENTS-1PROSPECTUS SUPPLEMENT SUMMARYS-2THE OFFERINGS-3RISK FACTORSS-5CAUTIONARY STATEMENTS REGARDING FORWARD-LOOKING STATEMENTSS-7USE OF PROCEEDSS-9SELLING STOCKHOLDERS-10MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES FOR NON-U.S. HOLDERS OFCOMMON STOCKS-11UNDERWRITING (CONFLICTS OF INTEREST)S-15LEGAL MATTERSS-20EXPERTSS-21WHERE YOU CAN FIND MORE INFORMATIONS-22INFORMATION INCORPORATED BY REFERENCES-23 ABOUT THIS PROSPECTUS1ABOUT THE COMPANY2RISK FACTORS3CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS4USE OF PROCEEDS6SELLING STOCKHOLDERS7PLAN OF DISTRIBUTION9LEGAL MATTERS11EXPERTS11WHERE YOU CAN FIND MORE INFORMATION11INCORPORATION OF CERTAIN INFORMATION BY REFERENCE12 Neither we, the underwriters, nor the selling stockholder have authorized anyone to provide any information or tomake any representations other than those contained in this prospectus supplement or the accompanying baseprospectus. Neither we, the underwriters, nor the selling stockholder takes any responsibility for, or provides anyassurance as to the reliability of, any other information that others may give you. Neither we, the underwriters, northe selling stockholder are making an offer of these securities in any state or jurisdiction where the offer is notpermitted. You should assume that the information appearing or incorporated by reference in this prospectussupplement, the accompanying prospectus or any free writing prospectus prepared by us is accurate only asof their respective dates or on the date or dates which are specified in such documents, and that anyinformation in documents that we have incorporated by reference is accurate only as of the date of suchdocument incorporated by reference. Our business, financial condition, liquidity, results of operations andprospects may have changed since those dates. For investors outside of the United States, neither we nor the selling stockholder have done anything that wouldpermit the offering, possession or distribution of this prospectus supplement in any jurisdiction where action for thatpurpose is required, other than in the United States. You are required to inform yourselves about and to observe anyrestrictions relating to the offering, possession or the distribution of this prospectus supplement outside of theUnitedStates. TABLE OF CONTENTS ABOUT THIS PROSPECTUS SUPPLEMENT This prospectus supplement and the accompanying base prospectus are part of a registration statement on FormS-3ASR (Registration No. 333-297701) that we filed with the Securities and Exchange Commission, or the SEC, usingan automatic “shelf” registration process. Under this “shelf” registration process, certain selling stockholders may,from time to time, sell any of the securities described in the accompanying base prospectus in oneor more offeringswith a maximum aggregate offering of up to 24,628,286 shares of common stock. The accompanying baseprospectus provides you with a general description of BridgeBio and the securities that may be offered by the sellingstockholders. Each time the selling stockholders sell securities under the registration statement through anunderwriter, dealer, or agent, a prospectus supplement will be provided that contains specific information about theterms of that offering. A prospectus supplement may also add, update, or change